SCHEMBL14299347

SCHEMBL14299347

[2H]c1c([2H])c([2H])c(C2CC(Cl)c3cc(Cl)ccc32)c([2H])c1[2H]

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.51
DRD1 P21728 3/20 0.51
HTR1A P08908 2/20 0.51
ADRA2A P08913 2/20 0.51
ADRA2B P18089 2/20 0.51
ADRA2C P18825 2/20 0.51
DRD4 P21917 2/20 0.51
DRD5 P21918 2/20 0.51
ADRA1D P25100 2/20 0.51
HTR2A P28223 2/20 0.51
HTR2C P28335 2/20 0.51
HTR7 P34969 2/20 0.51
ADRA1A P35348 2/20 0.51
HRH1 P35367 2/20 0.51
ADRA1B P35368 2/20 0.51
DRD3 P35462 2/20 0.51
HTR2B P41595 2/20 0.51
HTR6 P50406 2/20 0.51
SLC6A3 Q01959 2/20 0.51
CHRNB2 P17787 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15825706 1.00 DRD2 (0.51) DRD2DRD1HTR1AADRA2AADRA2B
SCHEMBL17272307 1.00 DRD2 (0.51) DRD2DRD1HTR1AADRA2AADRA2B
SCHEMBL15822843 1.00 DRD2 (0.51) DRD2DRD1HTR1AADRA2AADRA2B
SCHEMBL14299338 0.83 DRD2 (0.50) DRD2DRD1HTR1AADRA2AADRA2B
SCHEMBL14299346 0.83 DRD2 (0.50) DRD2DRD1HTR1AADRA2AADRA2B
SCHEMBL15821433 0.83 DRD2 (0.50) DRD2DRD1HTR1AADRA2AADRA2B
SCHEMBL2152822 0.79 DRD2 (0.49) DRD2DRD1HTR2AHTR2CHTR2B
SCHEMBL6055982 0.79 DRD2 (0.49) DRD2DRD1HTR2AHTR2CHTR2B
SCHEMBL2070013 0.79 DRD2 (0.49) DRD2DRD1HTR2AHTR2CHTR2B
SCHEMBL7320995 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2943460-B1 6-CHLORO-3-(PHENYL-D5)-INDEN-1-ONE AND USE THEREOF H LUNDBECK AS (DK) 2020-02-12 EP claimed
US-9309165-B2 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof H. LUNDBECK A/S (DK) 2016-04-12 US claimed
US-20150336867-A1 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof H. LUNDBECK A/S (DK) 2015-11-26 US claimed
EP-2943460-A2 6-CHLORO-3-(PHENYL-D5)-INDEN-1-ONE AND USE THEREOF H. Lundbeck A/S (DK) 2015-11-18 EP claimed
WO-2014096151-A2 6-CHLORO-3-(PHENYL-D5)-INDEN-1-ONE AND USE THEREOF H. LUNDBECK A/S (DK) 2014-06-26 WO claimed
US-12071416-B2 Prodrugs of 4-( (1R, 3S)-6-chloro-3-phenyl-2, 3-dihydro-1H-inden-1-yl)-1,2, 2-trimethylpiperazine and 4-( (1R, 3S)-6-chloro-3-(phenyl-D5)-2, 3-dihydro-1H-inden-1-yl)-2, 2-dimethyl-1 (methyl-D3) piperazine H. LUNDBECK A/S (DK) 2024-08-27 US disclosed
US-20230159478-A1 PRODRUGS OF 4- ( (1R, 3S) -6-CHLORO-3-PHENYL-2, 3-DIHYDRO-1H-INDEN-1-YL) -1,2, 2-TRIMETHYLPIPERAZINE AND 4- ( (1R, 3S)-6-CHLORO-3- (PHENYL-D5) -2, 3-DIHYDRO-1H-INDEN-1-YL) -2, 2-DIMETHYL-1 (METHYL-D3) PIPERAZINE H. LUNDBECK A/S (DK) 2023-05-25 US disclosed
US-11535600-B2 Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine H. LUNDBECK A/S (DK) 2022-12-27 US disclosed
US-20220033367-A1 PRODRUGS OF 4-((1R, 3S)-6-CHLORO-3-PHENYL-2,3-DIHYDRO-1H-INDEN-1-Y)-1-,2,2-TRIMETHYLPIPERAZINE AND 4-((1R,3S)-6-CHLORO-3-(PHENYL-D5)-2,3-DIHYDRO-1H-INDEN-1YL)-2,2-DIMETHYL-1 (METHYL-D3)PIPERAZINE H. LUNDBECK A/S (DK) 2022-02-03 US disclosed
EP-3891134-A1 PRODRUGS OF 4-((1R,3S)-6-CHLORO-3-PHENYL-2,3-DIHYDRO-1H-INDEN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND 4-((1/R,3S)-6-CHLORO-3-(PHENYL-D5)-2,3-DIHYDRO-1H-INDEN-1-YL)-2,2-DIMETHY-1-(METHYL-D3)PIPERAZINE H. Lundbeck A/S (DK) 2021-10-13 EP disclosed
WO-2020114853-A1 PRODRUGS OF 4-((1R,3S)-6-CHLORO-3-PHENYL-2,3-DIHYDRO-1H-INDEN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND 4-((1/R,3S)-6-CHLORO-3-(PHENYL-D5)-2,3-DIHYDRO-1H-INDEN-1-YL)-2,2-DIMETHY-1-(METHYL-D3)PIPERAZINE H. LUNDBECK A/S (DK) 2020-06-11 WO disclosed
EP-2943460-B1 6-CHLORO-3-(PHENYL-D5)-INDEN-1-ONE AND USE THEREOF H LUNDBECK AS (DK) 2020-02-12 EP disclosed
US-9309165-B2 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof H. LUNDBECK A/S (DK) 2016-04-12 US disclosed
US-20150336867-A1 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof H. LUNDBECK A/S (DK) 2015-11-26 US disclosed
EP-2943460-A2 6-CHLORO-3-(PHENYL-D5)-INDEN-1-ONE AND USE THEREOF H. Lundbeck A/S (DK) 2015-11-18 EP disclosed
WO-2014096151-A2 6-CHLORO-3-(PHENYL-D5)-INDEN-1-ONE AND USE THEREOF H. LUNDBECK A/S (DK) 2014-06-26 WO disclosed
US-8575174-B2 Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia H. LUNDBECK A/S (DK) 2013-11-05 US disclosed
US-20130281436-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA H. LUNDBECK A/S (DK) 2013-10-24 US disclosed
US-20120322811-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL-INDANES FOR TREATMENT OF SCHIZOPHRENIA H. LUNDBECK A/S (DK) 2012-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120322811-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL-INDANES FOR TREATMENT OF SCHIZOPHRENIA HTR2C, DRD2, HTR2A DRD2 2/4885DRD1 9/4885HTR1A 8/4885
US-20130281436-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA HTR2C, DRD2, HTR2A DRD2 2/4885DRD1 8/4885HTR1A 7/4885
US-12071416-B2 Prodrugs of 4-( (1R, 3S)-6-chloro-3-phenyl-2, 3-dihydro-1H-inden-1-yl)-1,2, 2-trimethylpiperazine and 4-( (1R, 3S)-6-chloro-3-(phenyl-D5)-2, 3-dihydro-1H-inden-1-yl)-2, 2-dimethyl-1 (methyl-D3) piperazine SIGMAR1, HTR3C, DRD3 DRD2 17/4885DRD1 58/4885HTR1A 102/4885
US-20150336867-A1 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof CYP2D6, UGT1A6, IDO1 DRD2 27/4885DRD1 23/4885HTR1A 67/4885
US-20220033367-A1 PRODRUGS OF 4-((1R, 3S)-6-CHLORO-3-PHENYL-2,3-DIHYDRO-1H-INDEN-1-Y)-1-,2,2-TRIMETHYLPIPERAZINE AND 4-((1R,3S)-6-CHLORO-3-(PHENYL-D5)-2,3-DIHYDRO-1H-INDEN-1YL)-2,2-DIMETHYL-1 (METHYL-D3)PIPERAZINE HTR1D, HTR3C, ITPR3 DRD2 21/4885DRD1 61/4885HTR1A 32/4885
US-11535600-B2 Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine HTR3C, ITPR3, HTR1D DRD2 17/4885DRD1 78/4885HTR1A 65/4885
US-20230159478-A1 PRODRUGS OF 4- ( (1R, 3S) -6-CHLORO-3-PHENYL-2, 3-DIHYDRO-1H-INDEN-1-YL) -1,2, 2-TRIMETHYLPIPERAZINE AND 4- ( (1R, 3S)-6-CHLORO-3- (PHENYL-D5) -2, 3-DIHYDRO-1H-INDEN-1-YL) -2, 2-DIMETHYL-1 (METHYL-D3) PIPERAZINE SIGMAR1, HTR3C, DRD3 DRD2 17/4885DRD1 58/4885HTR1A 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.